[1] Barnett R. Lung cancer [J]. Lancet (London, England), 2017, 390(10098): 928.
[2] Nasim F, Sabath B F, Eapen G A. Lung Cancer [J]. Med Clin North Am, 2019, 103(3): 463-73.
[3] O'leary K, Shia A, Schmid P. Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer [J]. Curr Cancer Drug Targets, 2018, 18(1): 89-96.
[4] Rabe K F, Watz H. Chronic obstructive pulmonary disease [J]. Lancet, 2017, 389(10082): 1931-40.
[5] Brown P J. The ravages of COPD [J]. The Lancet Respiratory medicine, 2018, 6(5): 336.
[6] Celli B R, Wedzicha J A. Update on Clinical Aspects of COPD. Reply [J]. The New England journal of medicine, 2019, 381(25): 2485-6.
[7] Zhong N S, Zeng G Q. Prevention and treatment of chronic respiratory diseases in China [J]. Chronic diseases and translational medicine, 2019, 5(4): 209-13.
[8] 2019 exceptional surveillance of lung cancer: diagnosis and management (NICE guideline NG122). London; National Institute for Health and Care Excellence (UK). 2019.
[9] Biswas A, Mehtaeh H J, FOLCH E E. Chronic obstructive pulmonary disease and lung cancer: inter-relationships [J]. Current opinion in pulmonary medicine, 2018, 24(2): 152-60.
[10] Jolly M K, Ward C, Eapen M S, et al. Epithelial-mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease [J]. Developmental dynamics : an official publication of the American Association of Anatomists, 2018, 247(3): 346-58.
[11] Sulaiman A, Yao Z M, Wang L S. Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression [J]. Journal of biomedical research, 2018, 32(2): 81-90.
[12] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition [J]. Nature reviews Molecular cell biology, 2014, 15(3): 178-96.
[13] Skrypek N, Goossans S, De Smedt E, et al. Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity [J]. Trends Genet, 2017, 33(12): 943-59.
[14] Sohal S S. Airway Basal Cell Reprogramming and Epithelial-Mesenchymal Transition: A Potential Key to Understanding Early Chronic Obstructive Pulmonary Disease [J]. Am J Respir Crit Care Med, 2018, 197(12): 1644-5.
[15] Eapen M S, Myers S, Lu W, et al. sE-cadherin and sVE-cadherin indicate active epithelial/endothelial to mesenchymal transition (EMT and EndoMT) in smokers and COPD: implications for new biomarkers and therapeutics [J]. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2018, 23(7): 709-11.
[16] Eapen M S, Sharma P, Thompson I E, et al. Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies [J]. Lab Invest, 2019, 99(2): 150-7.
[17] Mahmood M Q, Ward C, Muller H K, et al. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease [J]. Medical oncology (Northwood, London, England), 2017, 34(3): 45.
[18] Hou W, Hu S, Li C, et al. Cigarette Smoke Induced Lung Barrier Dysfunction, EMT, and Tissue Remodeling: A Possible Link between COPD and Lung Cancer [J]. BioMed research international, 2019, 2019(2025636.
[19] Zheng W, Jiang C, Li R. Integrin and gene network analysis reveals that ITGA5 and ITGB1 are prognostic in non-small-cell lung cancer [J]. Onco Targets Ther, 2016, 9(8): 2317-20.
[20] Ding Y, Pan Y, Liu S, et al. Elevation of MiR-9-3p suppresses the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via down-regulating FN1, ITGB1 and ITGAV [J]. Cancer Biol Ther, 2017, 18(6): 414-24.
[21] Wright D B, Meurs H, Dekkers B G J. Integrins: therapeutic targets in airway hyperresponsiveness and remodelling? [J]. Trends Pharmacol Sci, 2014, 35(11): 567-74.
[22] Plosa E J, Benjamin J T, Sucre J M, et al. β1 Integrin regulates adult lung alveolar epithelial cell inflammation [J]. JCI Insight, 2020, 5(2): 129259.
[23] Battaglia R A, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration [J]. F1000Res, 2018, 7(9): 1794-6.
[24] Bronte G, Puccetti M, Crinò L, et al. Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression [J]. Ann Oncol, 2019, 30(2): 339-40.
[25] Ye Z, Zhang X, Luo Y, et al. Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases [J]. PLoS One, 2016, 11(9): 163162-5.
[26] Li F J, Surolia R, Li H, et al. Low-dose cadmium exposure induces peribronchiolar fibrosis through site-specific phosphorylation of vimentin [J]. Am J Physiol Lung Cell Mol Physiol, 2017, 313(1): L80-L91.
[27] Mahmood M Q, Sohal S S, Shukla S D, et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction [J]. International journal of chronic obstructive pulmonary disease, 2015, 10(7): 1515-24.
[28] Yang S, Liu Y, Li M-Y, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer [J]. Mol Cancer, 2017, 16(1): 124-7.
[29] Dong Y Z, Meng X M, Li G S. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion [J]. Eur Rev Med Pharmacol Sci, 2018, 22(9): 2671-9.
[30] Li D, Xu T, Wang X, et al. The role of ATP8A1 in non-small cell lung cancer [J]. Int J Clin Exp Pathol, 2017, 10(7): 7760-6.
[31] Abd El-Fatah M F, Ghazy M A, Mostafa M S, et al. Identification of MMP-9 as a biomarker for detecting progression of chronic obstructive pulmonary disease [J]. Biochem Cell Biol, 2015, 93(6): 541-7.
[32] Wells J M, Parker M M, Oster R A, et al. Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene [J]. JCI Insight, 2018, 3(22): 123614.
[33] Zhou L, Le Y, Tian J, et al. Cigarette smoke-induced RANKL expression enhances MMP-9 production by alveolar macrophages [J]. International journal of chronic obstructive pulmonary disease, 2018, 14(6): 81-91.
[34] Zong D, Ouyang R, Li J, et al. Notch signaling in lung diseases: focus on Notch1 and Notch3 [J]. Ther Adv Respir Dis, 2016, 10(5): 468-84.
[35] Yuan X, Wu H, Xu H, et al. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis [J]. Scientific reports, 2015, 5(3): 10338-40.
[36] Gao Y P, Li Y, Li H J, et al. LncRNA NBR2 inhibits EMT progression by regulating Notch1 pathway in NSCLC [J]. Eur Rev Med Pharmacol Sci, 2019, 23(18): 7950-8.
[37] Zong D, Li J, Cai S, et al. Notch1 regulates endothelial apoptosis via the ERK pathway in chronic obstructive pulmonary disease [J]. Am J Physiol Cell Physiol, 2018, 315(3): C330-C40.
[38] Paraskevopoulou V, Papafotiou G, Klinakis A. KRT14 marks bladder progenitors [J]. Cell Cycle, 2016, 15(23): 3161-2.
[39] Arumugam A, Weng Z, Chaudhary S C, et al. Keratin-6 driven ODC expression to hair follicle keratinocytes enhances stemness and tumorigenesis by negatively regulating Notch [J]. Biochemical and biophysical research communications, 2014, 451(3): 394-401.
[40] Ooi A T, Mah V, Nickerson D W, et al. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer [J]. Cancer research, 2010, 70(16): 6639-48.
[41] Milara J, Peiró T, Serrano A, et al. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke [J]. 2013, 68(5): 410-20.
[42] Schamberger A C, Staab-Weijnitz C A, Mise-Racek N, et al. Cigarette smoke alters primary human bronchial epithelial cell differentiation at the air-liquid interface [J]. Scientific reports, 2015, 5(8): 8163-6.